Hyderabad:Pharma firm NATCO Pharma Limited has launched Everolimus tablets 1mg in the US. The product is a generic version of Zortress by Novartis. As per the BSE filing, NATCO’s marketing partner for the ANDA, Breckenridge Pharmaceutical, Inc., the U.S. subsidiary of Towa International, plans to launch the product immediately in the U.S. market. Everolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients in kidney and liver transplantation. Breckenridge previously launched its Everolimus Tablets in 0.25mg, 0.5mg, and 0.75mg strengths, with blisters launched in July 2021 and bottles launched in June 2023. Read also:Natco Gets SC Nod to Launch Generic Risdiplam at 80% Lower Price, Roche Appeal Dismissed
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!